CAS: 371242-69-2; 2-((6-Amino-9H-Purin-9-yl)Methyl)-5-Methyl-3-(O-Tolyl)Quinazolin-4(3H)-One

上下游产品

2-(氯甲基)-5-甲基-3-邻甲苯喹唑啉-4(3H)-酮 2-(Chloromethyl)-5-Methyl-3-(O-Tolyl)Quinazolin-4(3H)-One 371244-11-0

2-(氯甲基)-5-甲基-3-邻甲苯喹唑啉-4(3H)-酮,腺嘌呤置于potassium Carbonate体系中,用 Dmf (N,N-Dimethyl-Formamide) 用作溶剂,以20%的收率获得2-[(6-氨基-9H-嘌呤-9-基)甲基]-5-甲基-3-(2-甲基苯基)-4(3H)-喹唑啉酮
参考文献:Inhibitors Of Human Phosphatidylinositol 3-Kinase Delta
标题:Inhibitors Of Human Phosphatidylinositol 3-Kinase Delta
摘要:本文揭示了抑制磷脂酰肌醇3-激酶δ异构体(pi3Kδ)活性的方法,以及治疗疾病的方法,例如免疫和炎症紊乱,其中pi3Kδ在白细胞功能中发挥作用.最好的方法是使用能够选择性抑制pi3Kδ的活性的活性剂,同时不显著抑制其他pi3K异构体活性.提供了抑制pi3Kδ活性的化合物,包括选择性抑制pi3Kδ活性的化合物.还提供了使用pi3Kδ抑制剂化合物抑制癌细胞生长或增殖的方法.因此,本发明提供了使用pi3Kδ抑制剂化合物在体外和体内抑制pi3Kδ介导的过程的方法.

专利信息

专利号:US-12391691-B2
优先权日:2018-11-16
标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
发明人：PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
权利人:AMGEN INC
摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

专利号:US-2025206736-A1
优先权日:2019-11-14
标题 :Synthesis of kras g12c inhibitor compound
发明人：CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
权利人:AMGEN INC
摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

专利号:US-2025289827-A1
优先权日:2022-12-02
标 题:Morphic forms of a mutant braf degrader and methods of manufacture thereof
发明人：YU ROBERT T; HE MINSHENG; SCHNADERBECK MATTHEW J; KREGER BRIDGET; POLLOCK ROY MACFARLANE; JIANG SIYI; LI MEIQI; CHEN BOLU; LU JIANNAN
权利人:C4 THERAPEUTICS INC
摘要:Advantageous isolated morphic forms of (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane (Compound 1), which is a mutant BRAF degrader, and methods to prepare Compound 1 morphic forms for therapeutic applications are provided in the invention. The invention also provides improved methods for the synthesis of Compound 1, new pharmaceutical compositions comprising Compound 1, and new uses of Compound 1.

专利号:US-2023192681-A1
优先权日:2019-11-14
标 题 :Improved synthesis of kras g12c inhibitor compound

专利号:US-11299491-B2
优先权日:2018-11-16
标 题:Synthesis of key intermediate of KRAS G12C inhibitor compound

专利号:US-2025206735-A1
优先权日:2018-11-16
标题:Synthesis of key intermediate of kras g12c inhibitor compound